Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioDelivery Sciences International was a commercial-stage specialty pharmaceutical company focused on pain management and addiction medicine, leveraging proprietary drug delivery technologies for rapid transmucosal delivery. Its marketed products addressed significant unmet needs in chronic pain and opioid dependence. The company was acquired by Collegium Pharmaceutical in 2022 for approximately $604 million.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioDelivery Sciences International.